International RelationsEconomy
News 18 of 27

200% US Tariff Plan on Generic Medicines: India's $9.7B Pharma Export at Risk

Target:UPSC GS-IIMPSCSSC GATeachingBankingPrelims HighMains MediumStatic GK Link
22 Jul 2026
~2 min
Source: Indian Express
Key Data:$9.7 billion$25.8 billion38%200%0%100%
Bodies:Global Trade Research Initiative (GTRI)
Practice MCQs from today's news ▸
What This Article Covers

1.Trump announced a phased tariff plan on generic medicines: 0% for 2 years, 100% in year 3, and 200% from year 4 onward.

2.India exported $9.7 billion worth of pharmaceuticals to the US in 2025, accounting for 38% of India's total pharma exports.

3.Indian pharma stocks fell 2-2.5% in early trade, but analysts note that US-based subsidiaries may limit the tariff impact.

The Big Picture
Prelims · HighMains · Medium

US President Trump announced a phased tariff of up to 200% on generic drug imports to boost domestic manufacturing. India, the 'pharmacy of the world' with $9.7B in pharma exports to the US (38% of total), faces significant export disruption. However, US-based subsidiaries of Indian firms may reduce the direct impact.

Exam Lens

Quick Exam Facts From News

Tariff Plan Start DateAugust 1, 2026
Final Tariff Rate200%
India's Pharma Exports to US (2025)$9.7 billion
India's Total Pharma Exports (2025)$25.8 billion
US Share of India's Pharma Exports38%
Nifty Pharma Index DropNearly 2%

1-Minute Revision

  • ›Tariff Plan Start Date: August 1, 2026
  • ›Final Tariff Rate: 200%
  • ›Target this Data: India's pharma exports to US in 2025 = $9.7 billion (38% of total $25.8B)
  • ›Target this Data: Trump tariff timeline – 0% (2 yrs), 100% (year 3), 200% (from year 4)
  • ›Target this Institution/Report: Global Trade Research Initiative (GTRI) report cited for export data

Mastered this topic? Test your knowledge with a full MCQ quiz.

Practice exam-style questions, track your score, and strengthen your recall.

Q1Static LinkageEasy

Which of the following terms best describes drugs that are bioequivalent to a brand-name drug but sold without a brand name?

Q2Statement-basedHard

Consider the following statements regarding the US tariff plan on generic medicines announced by President Trump:

1. From August 1, 2026, generic drugs will face a 0% tariff for the first two years.

2. The tariff will rise directly to 200% from the first year onward.

3. The plan exempts patented, branded, and innovative drugs from the new tariff.

Which of the statements given above is/are correct?

Q3Data-centricMedium

What was the total value of India's pharmaceutical exports to the US in 2025, according to the Global Trade Research Initiative report?

Q4Application/ImpactMedium

Why might the direct impact of the US tariff on Indian pharmaceutical companies be lower than initially feared?

All 25 MCQs ▸
You finished this topic
Explore Related Topics
Related Current Affairs
Intl. Relations Current Affairs

US-China Summit: 2-Month Trade Truce Extension, AI Safety Off Agenda, India Faces Russian Oil Tariff Risk

Trump-Xi summit (Sept 23-24, 2026) resulted in a symbolic but substance-light outcome. AI safety was dropped from talks, a 2-month trade truce extension was agreed, and India faces increased tariff pressure for buying Russian crude oil as China gets a temporary exemption. The summit reinforces India's suspicion that it is the primary US target under the Lindsey O. Graham Sanctioning Russia and Iran Act.

Intl. Relations Current Affairs

US Imposes 100% Tariff on India Pharma Exports from 2028, Impact on $150 Bn Trade

Trump's unilateral tariff actions on Indian pharmaceutical exports (100% from 2028, rising to 200%) and use of Sections 301, 232, and 338 expose the fragility of ongoing India-US trade negotiations. Despite $150 billion bilateral trade and India's surplus, no signed agreement seems safe. India should prioritize trade diversification towards the UK and EU.

Economy Current Affairs

US Diesel Export Ban Proposal: Global Supply Crisis & Impact on India's Net Exporter Status

A US proposal to restrict diesel exports, supported by President Trump, threatens to remove the single largest source (20%) of globally traded diesel from the market. For India, a net diesel exporter, this could mean higher export margins for refineries like RIL, though higher export taxes and domestic demand will limit gains.

Economy Current Affairs

India-U.S. Trade Pact: Exporters Urge Early Conclusion, Tariff Uncertainty Hits Orders, Trade Surplus Narrows to $33.9 Bn

The Commerce Ministry met exporters to discuss India-U.S. trade performance and market access issues amidst ongoing bilateral trade agreement (BTA) negotiations. Exporters urged early conclusion of the pact to reduce tariff uncertainties, as U.S. buyers have reduced order volumes. The meeting also flagged concerns over U.S. safeguard measures on quartz surface products.

Economy Current Affairs

India Achieves Tariff Parity on Textile Exports with Bangladesh, Vietnam; Nine FTAs Cover $60 Trillion GDP

India's textile industry can no longer blame tariffs for poor export performance as Commerce Minister Piyush Goyal announced that India now enjoys tariff parity or advantage over competitors like Bangladesh and Vietnam in most developed markets, thanks to an expanding network of FTAs covering $60 trillion GDP.

Economy Current Affairs

Russia Accounts for 51% of India's Oil Imports in July 2026; US House Passes 100% Tariff Bill

India's reliance on Russian oil hit a record high of 51% in July 2026, even as the US House passed a bill to impose 100% tariffs on countries importing Russian oil. This poses a strategic dilemma for India's energy security and foreign policy.

Economy Current Affairs

US Sanctioning Act: 100% Tariff on India's Russian Oil Imports

The U.S. has enacted the Lindsey O. Graham Sanctioning Russia and Iran Act, 2026, which imposes a 100% tariff on goods from countries that continue to import Russian oil. India, a top importer, faces a strategic dilemma between its energy security needs and potential trade losses.

Intl. Relations Current Affairs

India, New Zealand Sign FTA: Key Tariff Cuts on Dairy, Pharma & Trade Pact Details

India and New Zealand have signed a Free Trade Agreement (FTA) aimed at boosting bilateral trade. This editorial analyzes the strategic timing, sectoral impacts (dairy, pharma, services), and the geopolitical context of the deal, which is crucial for understanding India's evolving trade policy and its implications for domestic industries.